论文部分内容阅读
美国 Centocor 公司研制的同位素标记单克隆抗体(McAb)能精确地显示心脏病发作后心脏的受损程度,并能检出癌症症状出现前微小癌细胞的生长情况。在同麻省总医院合作的一项研究中,给60名心脏病患者在心脏病发作后6小时注射抗肌凝蛋白 McAb.发现标记 McAb 可与心脏病发作期间细胞外膜受损释放的肌凝蛋白分子结合,通过放射活性显示出受损组织。标记 McAb 能识别严重受损和坏死心肌以及可复性的病理细胞。按照哈佛医学院 Gold 的观点,该技术能对患者是否值得作心脏外科手术作出准确的临床判
Isotope-labeled monoclonal antibodies (McAb) developed by the United States Centocor company can accurately show the extent of heart damage after a heart attack and can detect the growth of tiny cancer cells before the appearance of cancer symptoms. In a study co-authored with Massachusetts General Hospital, 60 patients with heart disease were injected with anti-Myosin McAb at 6 hours after a heart attack and found that the labeled McAb interacts with muscle released during injury to the extracellular membrane during a heart attack Conjugate molecules bind to show damaged tissue by radioactivity. The labeled McAb recognizes severely damaged and necrotic myocardium as well as refolding pathological cells. According to Gold at Harvard Medical School, this technique can provide an accurate clinical judgment of whether a patient is worthwhile for cardiac surgery